Idiopathic Pulmonary Fibrosis Market Growth Is Driven By Increasing...

Idiopathic Pulmonary Fibrosis Market Growth Is Driven By Increasing Prevalence Of Disease

Posted 2024-03-15 11:24:00

The idiopathic pulmonary fibrosis market has seen significant growth in recent years owing to the rising prevalence of the disease globally. Idiopathic pulmonary fibrosis is a lung disease that causes progressive scaring or thickening of lung tissue which makes breathing difficult. The exact cause of idiopathic pulmonary fibrosis is unknown in majority of cases but it mostly occurs in older adults. Some of the symptoms of IPF include shortness of breath, dry cough, fatigue and finger clubbing. If left untreated, the average life expectancy of an IPF patient is around 2-5 years. Currently, there is no cure for IPF but medications and oxygen therapy can help reduce symptoms and improve quality of life.

The Global Idiopathic Pulmonary Fibrosis Market is estimated to be valued at US$ 4,825.57 Billion in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Idiopathic Pulmonary Fibrosis Market Size are VISUfarma, Johnson & Johnson, Otsuka Holdings Co. Ltd., OASIS Medical, Novartis AG, Sentiss Pharma Pvt. Ltd., AbbVie Inc. (Allergan PLC), Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd., among others. The market leaders are focusing on developing innovative drug formulations and therapeutics to improve treatment outcomes.

There is growing demand for IPF therapeutics globally owing to increasing incidence of IPF cases worldwide. According to the World Health Organization, globally about 5 million people are estimated to be living with IPF and it is more prevalent in developed nations.

The idiopathic pulmonary fibrosis market is also expanding rapidly in developing regions of Asia Pacific and Latin America. This is attributed to rising healthcare expenditures, growing awareness about IPF, and increasing accessibility to diagnosis and treatment in these developing countries.

Market drivers

Increasing prevalence of IPF due to growing geriatric population globally is a major market driver. Older age is the strongest risk factor for developing IPF. According to the Public Health Agency of Canada, more than 50% of IPF patients are over 65 years old. Additionally, continuous launches of novel drug formulations with improved efficacy is also fueling the growth of this market. For instance, in 2019, OFEV (nintedanib) was the first drug to be approved by the FDA for treatment of IPF in nearly 15 years, opening up new opportunities in this market.

Impact of geopolitical situation on Idiopathic Pulmonary Fibrosis market growth and geographical regions

The current geopolitical instability and economic uncertainties caused by the ongoing Russia-Ukraine war is negatively impacting the growth of the Idiopathic Pulmonary Fibrosis market. Countries involved in the conflict are witnessing disruptions in trade and supply chains due to sanctions imposed by Western nations. This is affecting both availability and affordability of drugs used for IPF treatment. Production of raw materials required for drug formulation has also been impacted leading to shortages. Prices of drugs have increased significantly due to rising transportation costs and shortage of ingredients. The depreciation of currencies in conflict regions has further reduced purchasing power of consumers.

To counter these challenges, manufacturers need to diversify their supply networks and establish facilities in politically stable regions not directly impacted by the war. They also need to stock adequate inventory of raw materials required for longer term to hedge against future supply risks arising from geopolitical conflicts. Pharma companies will have to explore alternative sourcing options and efficiently manage their supply chain to ensure consistent availability of drugs. Price control measures may also need to be considered to maintain affordability of treatment.

North America currently represents the most concentrated region for the Idiopathic Pulmonary Fibrosis market in terms of value, accounting for over 40% share. This can be attributed to developed healthcare infrastructure, growing awareness about IPF, rising adoption of new therapeutic drugs and larger patient pool in the US and Canada. However, Asia Pacific region is emerging as the fastest growing market driven by increasing healthcare spending, rising disposable income, growing geriatric population and improving access to diagnosis and treatment in major countries like China, India and South Korea.

Geographical regions with high Idiopathic Pulmonary Fibrosis market value

North America is currently the largest and most valuable region for the global Idiopathic Pulmonary Fibrosis market. The region accounted for over 40% market share in terms of value in 2024. This can be attributed to developed healthcare infrastructure, rising healthcare spending, growing patient awareness about idiopathic pulmonary fibrosis (IPF), availability of advanced treatment options and presence of global pharmaceutical industry leaders in the US and Canada. Increased adoption of novel therapeutic drugs along with growing diagnosis rates will continue to drive high demand for IPF medication in North America over the forecast period to 2031.

Europe is the second major market globally, owing to universal healthcare coverage, large patient pool affected by IPF especially in Germany, France, UK and Italy, and launch of innovative treatment methods approved by regulatory authorities. Countries in Asia Pacific are expected to emerge as the fastest growing regional markets for Idiopathic Pulmonary Fibrosis in the coming years.

Fastest growing region for Idiopathic Pulmonary Fibrosis market

The Asia Pacific region is poised to exhibit strongest growth in the global Idiopathic Pulmonary Fibrosis market during 2024-2031. Factors such as rising disposable income, growing health awareness, increasing government expenditure on healthcare, rapidly ageing population prone to IPF, and improving access to advanced treatment are fueling high demand for IPF drugs in Asia Pacific countries.

Especially, China and India represent highly lucrative markets owing to the large patient populations affected by IPF, emerging biopharmaceutical industries and progressive reforms in healthcare systems to provide universal access to treatment. Growing medical tourism from other regions and initiatives by leading global pharmaceutical players to strengthen distribution networks in Asia are also supporting the regional market expansion.

In addition, other Asia Pacific nations including South Korea, Japan, Australia, Indonesia and Malaysia are anticipated to witness a steady rise in IPF diagnoses and drug requirement over coming years, as environmental pollution related chronic lung diseases escalate. Significant unmet needs in rural regions and scope for upgrading diagnostic capabilities will create further opportunities. The Asia Pacific Idiopathic Pulmonary Fib